ALC Alcon Vision Earnings per share for the last twelve months

Public company logo of Alcon Vision (ALC)

Alcon Inc. generates revenue through the sale of surgical instruments, cataract correction lenses, and eye care products. The TTM annual earnings per share metric helps filter out market noise, while the 1.31 value confirms the current yield level. The business is protected by stable demand for medical products without seasonal fluctuations, while growth is driven by the targeted acquisition of tech startups.

ALC (Alcon Inc.) Net earnings per share (EPS TTM) history from 07/04/2022 to 11/11/2026

ALC (Alcon Inc): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Price Alcon Inc.|ALC - Average Forecast Price
- market capitalization data:
Market Value Alcon Inc.|ALC - Company Buyout Price
- shareholders' equity book value data:
Book Value per Share Alcon|ALC - Book Capitalization|Market Value to Book Value Ratio alcon.com|ALC - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Alcon Inc.|ALC - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Alcon Vision|ALC - Company Cumulative Debt|Debt to Book Capitalization Ratio Alcon Inc.|ALC - Company Long-Term Indebtedness|Company Current Liabilities Alcon|Quick Ratio alcon.com
- net income and valuation multiples indicators:
ALC - Net Financial Result|Expected Profit Alcon Inc.|ALC - Price to Earnings Multiple|Forward P/E Multiple Alcon|ALC - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Alcon Inc.|ALC - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Alcon|ALC - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months alcon.com|ALC - Earnings per share growth in current year|Earnings growth forecast for next year Alcon Inc.
Basic company analysis:ALC - Alcon Inc.
Manufactured products of Alcon Vision

Portfolio managers value the operating model of Alcon Inc. (ALC), where trailing twelve-month earnings per share (EPS TTM) serves as the metric for real return on equity, stripped of the impact of share issuance. This rolling 12-month EPS chart confirms that structural demand for ophthalmology technologies is converting into sustainable profit growth, cementing the issuer's dominant position in the global market.

Direct competitors

Bausch + Lomb Corporation - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months glaukos.com|Apellis (APLS) - Earnings per share for the last twelve months|BLTE - Net earnings per share for the last four quarters|OCUL (Ocular Therapeutix Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Harrow Corp|Earnings per share for the last twelve months Viridian Therapeutics (VRDN)|Earnings per share for the last twelve months LENZ (lenz-tx.com)|Net earnings per share (EPS TTM) OCS (Oculis Holding)|EYPT - Net earnings per share for the last 12 months|KOD - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Aldeyra Therapeutics|kalarx.com (KALA) - Earnings per share for the last twelve months|Earnings per share for the last 12 months IRD|Net earnings per share for the last 12 months OKYO|ADVM: Earnings per share for the trailing year|Net earnings per share (EPS TTM) OTLK|Net earnings per share for the last four quarters Clearside Corp|Earnings per share for the last twelve months NovaBay Pharmaceuticals, Inc. NBY|KPRX: Earnings per share for the last 12 months|Alimera - Net earnings per share (EPS TTM)|Eyenovia, Inc. (EYEN) - Net earnings per share for the last 12 months|GHSI (Guardion Health Sciences Inc.) - Net earnings per share for the last 12 months|OCUP - Net earnings per share for the last four quarters|OPT (Opthea Limited) - Net earnings per share (EPS TTM)